Related Experiment Videos
Octreotide administration in diabetic rats: effects on renal function and morphology
T Usenmez1, O Yildiz, C Oktenli
1Department of Internal Medicine, Gülhane School of Medicine, Ankara, Turkey.
Journal of Diabetes and Its Complications
|August 5, 2000
Summary
Octreotide treatment in diabetic rats prevented kidney weight gain but did not improve urinary protein excretion or histopathological changes. This synthetic somatostatin analogue showed limited efficacy in mitigating diabetic nephropathy markers.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic nephropathy is a significant complication of diabetes mellitus, characterized by changes in kidney weight, protein excretion, and glomerular filtration rate.
- Synthetic somatostatin analogues, such as octreotide, are used in various endocrine conditions, but their specific effects on diabetic kidney disease require further investigation.
Purpose of the Study:
- To evaluate the impact of octreotide on key markers of kidney function and morphology in a rat model of alloxan-induced diabetes.
Main Methods:
- Diabetic rats received daily subcutaneous injections of octreotide (5 microg/day) for 90 days.
- Measurements included fractional kidney weight (FKW), urinary protein excretion (UPE), and creatinine clearance (Cl(cre)).
- Renal histopathology was assessed at the end of the study period.
Main Results:
- Octreotide administration prevented the significant increase in FKW observed in untreated diabetic rats.
- While creatinine clearance (Cl(cre)) was initially lower in octreotide-treated rats, no significant difference was noted by day 90.
- Octreotide showed minimal effect on reducing urinary protein excretion (UPE) and did not prevent diabetes-related histopathological kidney damage.
Conclusions:
- Daily octreotide treatment for 90 days in diabetic rats successfully mitigated kidney weight increase.
- However, the treatment was insufficient to reverse or prevent significant histopathological changes, reduce urinary protein excretion, or normalize creatinine clearance.
- These findings suggest limited therapeutic benefit of octreotide in managing established diabetic nephropathy markers in this model.